Business Wire

WisdomTree Files Preliminary Proxy Statement

Share

WisdomTree, Inc. (NYSE: WT) (“WisdomTree” or the “Company”), a global financial innovator, today announced that it has filed preliminary proxy materials on Schedule 14A with the Securities and Exchange Commission (“SEC”) in connection with WisdomTree’s 2023 Annual Meeting of Stockholders (“2023 Annual Meeting”). At this meeting, WisdomTree stockholders will have the opportunity to vote to elect six highly qualified nominees to the Company’s nine-member Board of Directors (“Board”), and on other important matters.

The Board’s six highly qualified nominees standing for election bring extensive experience relevant to WisdomTree’s business strategy, including global financial, accounting, compliance, cybersecurity and digital expertise, and many years in senior leadership positions in the investment management and financial services industry:

  • Lynn S. Blake: New independent director since May 2022 with decades of experience in the ETF industry, asset management and ESG
  • Daniela Mielke: New independent director since September 2022 with decades of experience growing financial services, payments and fintech companies
  • Shamla Naidoo: New independent director nominee who will bring to WisdomTree deep expertise in digital transformation and cybersecurity
  • Win Neuger: Independent investor and consultant who contributes to the Board a stockholder perspective with investment expertise
  • Frank Salerno: Independent Chair of the Board who possesses extensive corporate governance and asset management expertise
  • Jonathan Steinberg: CEO and Founder of WisdomTree, responsible for the creation and development of WisdomTree’s proprietary index methodology, and growing the Company into a leading global financial innovator with approximately $91.9 billion in assets under management

In the preliminary proxy statement, the Company describes the expertise and background of its nominees standing for election, and outlines the significant efforts taken by the Board and its Nominating and Governance Committee to bring fresh perspectives to the boardroom, including the addition of five new directors since January 2021.

Frank Salerno, Chair of the WisdomTree Board of Directors, said, “We are excited to introduce stockholders to Shamla Naidoo, an extraordinarily well-qualified director with expertise in cybersecurity and digital innovation that is a perfect match for our strategy. She will be extremely additive as WisdomTree continues its expansion into the rapidly growing digital financial services sector, including the upcoming launch of WisdomTree Prime™, and further capitalizes on our first mover status. We are fortunate to be able to continue to add directors of such high caliber as Shamla Naidoo, Daniela Mielke and Lynn Blake, as well as Smita Conjeevaram and Harold Singleton III. The Board remains committed to ongoing Board refreshment, as well as prioritizing diversity.”

Shamla Naidoo is a technology industry veteran with experience helping businesses across diverse sectors and cultures use technology more effectively. She has successfully embraced and led digital strategy in executive leadership roles, including Chief Information Security Officer (CISO), at companies such as International Business Machines Corp. (IBM), Elevance Health, Inc. (previously WellPoint, Inc.), Marriott International, Inc. (previously Starwood Hotels & Resorts, Inc.) and Northern Trust Corporation.

Shamla has helped organizations in over 20 countries recognize the impact of digital transformation globally and advise their stakeholders on predicting and navigating the necessary changes in laws and regulations. In addition, she has worked with intelligence communities to use digital and cyber within their organizations to protect businesses and society from technology misuse.

WisdomTree stockholder ETFS Capital Limited (“ETFS Capital”) owns shares with the right to vote 10.2% of the Company’s common stock at the 2023 Annual Meeting and has nominated three individuals to the Company’s Board: Bruce E. Aust, Tonia Pankopf and ETFS Capital’s chairman Graham Tuckwell AO. After evaluating ETFS Capital’s nominees in accordance with its established protocols, the WisdomTree Board does not view Mr. Tuckwell as a suitable addition to the Board. He misunderstands the Company’s business and vision and lacks the track record, public company experience and temperament to serve as a public company director or enhance the Board. Mr. Tuckwell also has significant conflicts of interest that put him at odds with the interests of other WisdomTree stockholders. The Board further believes that Mr. Aust and Ms. Pankopf would not add any skills or competencies to the Board that the current Board members collectively do not already possess.

Under the SEC’s universal proxy card rules, the WisdomTree nominees will appear on the Company’s proxy card along with the three individuals nominated by dissident stockholder ETFS Capital. Stockholders will be able to decide which director nominees will best represent their interests and guide the Company forward.

Advisors

BofA Securities is serving as financial advisor, and Goodwin Procter LLP is serving as legal counsel to WisdomTree. Innisfree M&A is serving as proxy solicitor and H/Advisors Abernathy is serving as strategic communications advisor.

About WisdomTree

WisdomTree is a global financial innovator, offering a well-diversified suite of exchange-traded products (ETPs), models and solutions. We empower investors to shape their future and support financial professionals to better serve their clients and grow their businesses. WisdomTree is leveraging the latest financial infrastructure to create products that provide access, transparency and an enhanced user experience. Building on our heritage of innovation, we are also developing next-generation digital products and structures, including digital funds and tokenized assets, as well as our blockchain-native digital wallet, WisdomTree Prime™.

WisdomTree currently has approximately $91.9 billion in assets under management globally.

WisdomTree® is the marketing name for WisdomTree, Inc. and its subsidiaries worldwide.

Cautionary Statement Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” “views,” and similar expressions. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, the impact and contributions of the slate of director nominees WisdomTree has nominated, and WisdomTree’s ability to achieve its financial and business plans, goals and objectives and drive stockholder value, including with respect to its ability to successfully implement its strategy relating to WisdomTree Prime™, and other risk factors discussed from time to time in WisdomTree’s filings with the SEC, including those factors discussed under the caption “Risk Factors” in its most recent annual report on Form 10-K, filed with the SEC on February 28, 2023, and in subsequent reports filed with or furnished to the SEC. WisdomTree assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.

Important Additional Information and Where to Find It

WisdomTree intends to file a proxy statement on Schedule 14A, an accompanying WHITE proxy card and other relevant documents with the SEC in connection with such solicitation of proxies from WisdomTree stockholders for WisdomTree’s 2023 Annual Meeting. WISDOMTREE STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ WISDOMTREE’S DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO), ACCOMPANYING WHITE PROXY CARD, AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and stockholders may obtain a copy of the definitive proxy statement, an accompanying WHITE proxy card, any amendments or supplements to the definitive proxy statement and other documents that WisdomTree files with the SEC at no charge at the SEC’s website at www.sec.gov. Copies will also be available at no charge on WisdomTree’s Investor Relations website at https://ir.wisdomtree.com/sec-filings or by contacting Jeremy Campbell, Head of Investor Relations, at jeremy.campbell@wisdomtree.com, as soon as reasonably practicable after such materials are electronically filed with, or furnished to, the SEC.

Certain Information Regarding Participants in the Solicitation

WisdomTree, its directors and certain of its executive officers may be deemed participants in the solicitation of proxies from WisdomTree stockholders by WisdomTree in connection with matters to be considered at WisdomTree’s 2023 Annual Meeting. Information regarding the direct and indirect interests, by security holdings or otherwise, of WisdomTree’s directors and executive officers, in WisdomTree is included in WisdomTree’s definitive proxy statement on Schedule 14A for its 2022 annual meeting of stockholders, filed with the SEC on June 10, 2022, WisdomTree’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on February 28, 2023, and in WisdomTree’s Current Reports on Form 8-K filed with the SEC from time to time. Changes to the direct or indirect interests of WisdomTree’s directors and executive officers are set forth in SEC filings on Initial Statements of Beneficial Ownership of Securities on Form 3, Statements of Changes in Beneficial Ownership on Form 4 and Annual Statements of Changes in Beneficial Ownership of Securities on Form 5. These documents are available free of charge as described above. Updated information regarding the identities of potential participants and their direct or indirect interests, by security holdings or otherwise, in WisdomTree will be set forth in WisdomTree’s definitive proxy statement for WisdomTree’s 2023 Annual Meeting and other relevant documents to be filed with the SEC, if and when they become available.

Category: Business Update

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investor Relations
WisdomTree, Inc.
Jeremy Campbell
+1.646.522.2602
Jeremy.campbell@wisdomtree.com

or

Innisfree M&A Incorporated
Jonathan Salzberger / Scott Winter
+1.212.750.5833
jsalzberger@innisfreema.com / swinter@innisfreema.com

Media Relations
WisdomTree, Inc.
Jessica Zaloom
+1.917.267.3735
jzaloom@wisdomtree.com / wisdomtree@fullyvested.com

or

H/Advisors Abernathy
Jeremy Jacobs / Dana Gorman
+1.202.774.5600 / +1.212.371.5999
jeremy.jacobs@h-advisors.global / dana.gorman@h-advisors.global

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Positive Phase 3 Results Support ZIIHERA ® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA ® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 13:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including cancers of the stomach, gastroesophageal junction, and esophagus. Both ZIIHERA plus TEVIMBRA and chemotherapy and ZIIHERA plus chemotherapy demonstrated clinically meaningful and highly statistically significant improvements in progression-free survival (PFS) compared to the control arm, trastuzumab plus chemotherapy. ZIIHERA plus TEVIMBRA and chemotherapy also demonstrated clinically meaningful and statistically significant improvements in overall survival (OS), and ZIIHERA plus chemotherapy demonstrated a clinically meaningful eff

Global Winners of the 2025–2026 World Branding Awards Announced at First-Ever Japan Ceremony17.11.2025 12:43:00 EET | Press release

Now in its 20th edition, the World Branding Awards continues to spotlight the world’s most impactful and trusted brands. This year, over 1,092 brands from 66 countries were nominated as “Brand of the Year”, with less than 100 declared Winners across Global, Regional, and National tiers. The World Branding Awards Ceremony stepped outside London for the first time, bringing its global presence to the Osaka City Museum of Fine Arts. The 2025–2026 edition welcomed over 80 international guests and was presented by the acclaimed Allie Sakakibara. The evening was further elevated by a keynote presentation from Miho Noguchi, who shared insights on building emotional resonance through immersive brand experiences. Global Tier winners celebrated their outstanding branding excellence across various industries, including IKEA (Sweden), Lurpak (Denmark), Marriott International (United Kingdom), Nike (USA), Sennheiser (Germany), and Yakult (Japan). These brands consistently demonstrated strength, inf

Henlius and Organon Announce US FDA Approval of POHERDY ® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US17.11.2025 12:30:00 EET | Press release

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection for intravenous use, an interchangeable biosimilar to PERJETA (pertuzumab), for all indications of the reference product.1 POHERDY is the first and only approved pertuzumab biosimilar in the US, representing an important milestone in expanding access to quality and potentially more affordable biologic therapies for patients with certain HER2-positive breast cancers.2 "Expanding access to treatments for diseases that disproportionately impact women, including breast cancer, the most common cancer among women in the US excluding skin cancer, is at the core of our mission,” said Jon Martin, US Commercial Lead, Biosimilars and Established Brands at Organon.3 “Not only is POHERDY the first approved biosimilar to PERJETA in the US, but its approval also builds

WEX ® Unlocks Access to 20,000+ Tesla Superchargers Across Europe17.11.2025 12:15:00 EET | Press release

WEX® (NYSE: WEX), the global commerce platform that simplifies the business of running a business, today announced integration with the Tesla Supercharger network, adding over 20,000 fast-charging points across 1,500+ locations to its platform. The move significantly expands charging options for WEX’s customers, particularly in areas where high-power charging has been limited or expensive. By bringing Tesla Superchargers into their ecosystem, WEX gives drivers access to competitively priced fast charging with speeds up to 250 kW, increasing availability of high-power charging stations by 10%. WEX customers already use the EV Driver by WEX app to charge at over 1 million charging points throughout Europe. Now, they can access Tesla Superchargers with the same seamless experience: comparing real-time pricing across all networks, planning optimal routes, tracking sessions, and managing payments in one unified platform - regardless of the charging network they choose. “Providing access to

Global Cement Industry Reports 25% CO 2 Intensity Reduction and Calls for Urgent Government Action to Accelerate Net Zero Mission17.11.2025 12:00:00 EET | Press release

The extensive decarbonisation work being carried out by the global cement and concrete industry to cut CO₂ emissions is set out in a new global report launched at COP30 in Belem, Brazil. The report details latest industry data showing that the sector is making progress, and also emphasises the need for urgent global government input to help accelerate action. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117920702/en/ GCCA Cement and Concrete Industry Net Zero Action and Progress Report The report finds that the industry has reduced the CO₂ intensity of cementitious products by 25% across the globe since 1990, and also sets out a series of policy recommendations that can pave the way for faster reductions. Dominik von Achten GCCA President and Chairman of the Managing Board of Heidelberg Materials said: "Our industry is collaborating and innovating across every aspect of our manufacturing – finding new ways to work and d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye